A new USC Schaeffer Center paper highlights tactics used by intermediaries in the pharmaceutical distribution system, including pharmacy benefit managers (PBMs) and insurers, that are costing patients, employers and the government billions for what should be inexpensive medicines.
Other featured articles
Patients Deserve Immediate Access to FDA-Approved Innovations — Not Bureaucratic Restrictions
Nonresident Senior Fellow Joe Grogan argues that the FDA approval process is slowing down drug innovation.
Value Defects In The Health Services Sector
As of 2021, US health care expenditures exceed $3.8 trillion. It’s no secret that health care is nearly as wasteful in spending on value defects—behaviors that needlessly reduce quality, negatively impact the patient experience, or add to total costs of care—as it is in delivering clinical benefits.
Stabilizing Health Care’s Share of the GDP
Since 1960, health care’s share of the GDP has risen by an average of 2.2 percentage points per decade, as compared with an average increase of 1.1 percentage points per decade in 15 other high-income countries since the early 1970s.
Injuries Due to Medical Error are Common. They Could Be Prevented by Reducing Complexity
Research shows that medical error is the third leading cause of death worldwide.
About this section
Healthcare reform should hinge on improving value, reducing waste, and bettering the health outcomes of patients. The Schaeffer Center is a pioneer in posing solutions to enhance the value of healthcare services and expand their reach.